– UK, Chichester – Deltex Medical Group plc (LON: DEMG), the global leader in oesophageal Doppler monitoring, today announced the appointment of Professor Tim Irish to its Board of Directors with immediate effect.
“I am very pleased to welcome Tim Irish back to the Board. He brings with him great experience in medical device businesses coupled with insights into the way that the NHS adopts new technologies gained from his time as Vice-Chair of NICE. This is particularly significant for Deltex as haemodynamic management becomes increasingly important in the successful management of patients admitted to hospital with COVID-19.” said Board Chairman, Nigel Keen.
About Professor Tim Irish
Tim has worked in the life sciences industry for 30 years. His career has spanned global health technology companies across Europe and North America, including GSK, GE and Philips. Between 2007 and 2015 he served on 10 Boards, 5 of which as Chair.
Tim’s current appointments cover life sciences and healthcare, both public and private, including his Board role at NICE where he is Vice-Chair, various European med-tech supervisory board roles, and Professor of practice at King’s College London’s School of Management and Business.
About Deltex Medical
Deltex Medical manufactures and markets haemodynamic monitoring technologies which are primarily used in critical care and general surgical procedures. Deltex Medical’s proprietary oesophageal Doppler monitoring measures blood flow velocity in the central circulation in real time. Minimally invasive, easy to set-up and quick to focus, the technology generates a low-frequency ultrasound signal which is highly sensitive to changes in blood flow and measures such changes in ‘real time’. Deltex Medical is the only company in the enhanced haemodynamic space to have built a robust and credible evidence base demonstrating both the clinical and economic benefits of its core technology: TrueVue Doppler. This technology has been proven in a wide range of clinical trials to reduce complications suffered by patients after surgery and consequently can save hospitals money.
Deltex Medical’s TrueVue System on the CardioQ-ODM+ monitor platform now provides clinicians with two further advanced haemodynamic monitoring technologies. TrueVue Impedance is an entirely non-invasive monitoring technology which transmits low magnitude, high frequency electrical signals through the thorax and measures the changes to this signal when the heart pumps blood. TrueVue PressureWave uses the peripheral blood pressure signal analysis to give doctors information on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamically stable patients.
For more information : https://www.deltexmedical.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
